353 related articles for article (PubMed ID: 23102915)
21. Role of microRNAs in kidney homeostasis and disease.
Chandrasekaran K; Karolina DS; Sepramaniam S; Armugam A; Wintour EM; Bertram JF; Jeyaseelan K
Kidney Int; 2012 Apr; 81(7):617-27. PubMed ID: 22237749
[TBL] [Abstract][Full Text] [Related]
22. Advances in early biomarkers of diabetic nephropathy.
Zhang J; Liu J; Qin X
Rev Assoc Med Bras (1992); 2018 Jan; 64(1):85-92. PubMed ID: 29561946
[TBL] [Abstract][Full Text] [Related]
23. Study of microRNA in diabetic nephropathy: isolation, quantification and biological function.
Kantharidis P; Hagiwara S; Brennan E; McClelland AD
Nephrology (Carlton); 2015 Mar; 20(3):132-9. PubMed ID: 25487691
[TBL] [Abstract][Full Text] [Related]
24. MicroRNAs: potential therapeutic targets in diabetic complications of the cardiovascular and renal systems.
Figueira MF; Monnerat-Cahli G; Medei E; Carvalho AB; Morales MM; Lamas ME; da Fonseca RN; Souza-Menezes J
Acta Physiol (Oxf); 2014 Jul; 211(3):491-500. PubMed ID: 24837225
[TBL] [Abstract][Full Text] [Related]
25. [Care of patients with diabetic nephropathy].
Boucek P
Cas Lek Cesk; 1997 Nov; 136(22):689-92. PubMed ID: 9476380
[TBL] [Abstract][Full Text] [Related]
26. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function.
Lajer M; Tarnow I; Michelson AD; Jorsal A; Frelinger AL; Parving HH; Rossing P; Tarnow L
Platelets; 2010; 21(7):525-32. PubMed ID: 20701458
[TBL] [Abstract][Full Text] [Related]
27. [Current issues in the diagnosis and therapy of diabetic nephropathy].
de Châtel R; Mogyorósi A; Ziyadeh FN
Orv Hetil; 1997 Jan; 138(4):187-93. PubMed ID: 9072751
[TBL] [Abstract][Full Text] [Related]
28. The effects of expression of different microRNAs on insulin secretion and diabetic nephropathy progression.
Mafi A; Aghadavod E; Mirhosseini N; Mobini M; Asemi Z
J Cell Physiol; 2018 Jan; 234(1):42-50. PubMed ID: 30078212
[TBL] [Abstract][Full Text] [Related]
29. Review: Endothelial-myofibroblast transition, a new player in diabetic renal fibrosis.
Li J; Bertram JF
Nephrology (Carlton); 2010 Aug; 15(5):507-12. PubMed ID: 20649869
[TBL] [Abstract][Full Text] [Related]
30. Progression of chronic renal disease and diabetic nephropathy: a review of clinical studies and current therapy.
Marinides GN
J Med; 1993; 24(4-5):266-88. PubMed ID: 8258740
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update.
Arora MK; Singh UK
Vascul Pharmacol; 2013 Apr; 58(4):259-71. PubMed ID: 23313806
[TBL] [Abstract][Full Text] [Related]
32. Urinary cystatin C as a biomarker for diabetic nephropathy and its immunohistochemical localization in kidney in Zucker diabetic fatty (ZDF) rats.
Togashi Y; Miyamoto Y
Exp Toxicol Pathol; 2013 Jul; 65(5):615-22. PubMed ID: 22795897
[TBL] [Abstract][Full Text] [Related]
33. Drug discovery for diabetic nephropathy: trying the leap from mouse to man.
Breyer MD
Semin Nephrol; 2012 Sep; 32(5):445-51. PubMed ID: 23062985
[TBL] [Abstract][Full Text] [Related]
34. Inflammation and the pathogenesis of diabetic nephropathy.
Wada J; Makino H
Clin Sci (Lond); 2013 Feb; 124(3):139-52. PubMed ID: 23075333
[TBL] [Abstract][Full Text] [Related]
35. miRNA signatures in diabetic retinopathy and nephropathy: delineating underlying mechanisms.
Kaur P; Kotru S; Singh S; Munshi A
J Physiol Biochem; 2022 Feb; 78(1):19-37. PubMed ID: 35098434
[TBL] [Abstract][Full Text] [Related]
36. The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications.
Navarro JF; Mora-Fernández C
Cytokine Growth Factor Rev; 2006 Dec; 17(6):441-50. PubMed ID: 17113815
[TBL] [Abstract][Full Text] [Related]
37. Urinary MCP-1 and RBP: independent predictors of renal outcome in macroalbuminuric diabetic nephropathy.
Titan SM; Vieira JM; Dominguez WV; Moreira SR; Pereira AB; Barros RT; Zatz R
J Diabetes Complications; 2012; 26(6):546-53. PubMed ID: 22981148
[TBL] [Abstract][Full Text] [Related]
38. Progression of diabetic nephropathy in type 1 diabetic patients.
Najafian B; Mauer M
Diabetes Res Clin Pract; 2009 Jan; 83(1):1-8. PubMed ID: 19070384
[TBL] [Abstract][Full Text] [Related]
39. The role of microRNAs in diabetic nephropathy.
Wu H; Kong L; Zhou S; Cui W; Xu F; Luo M; Li X; Tan Y; Miao L
J Diabetes Res; 2014; 2014():920134. PubMed ID: 25258717
[TBL] [Abstract][Full Text] [Related]
40. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
Arora MK; Reddy K; Balakumar P
Eur J Pharmacol; 2010 Jun; 636(1-3):137-44. PubMed ID: 20347778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
